Nathan Grimes1, Cathal Hannan2, Matthew Tyson3, Ali Thwaini4. 1. Forth Valley Royal Hospital, Larbert, Scotland. 2. Royal Victoria Hospital, Belfast, Northern Ireland. 3. Craigavon Area Hospital, Craigavon, Northern Ireland. 4. Belfast City Hospital, Belfast, Northern Ireland.
Abstract
INTRODUCTION: Prognosis in patients with cancer is influenced by underlying tumour biology and also the host inflammatory response to the disease. There is limited evidence to suggest that an elevated neutrophil-lymphocyte ratio (NLR) predicts a poorer prognosis in patients undergoing nephrectomy for renal cell carcinoma (RCC). The aim of this paper is to investigate if patients undergoing nephrectomy for RCC with NLR ≤4 have a better overall and recurrence-free survival than patients with NLR >4. METHODS: All patients who underwent nephrectomy at a single centre between January 1, 2011 and December 31, 2014 were identified. Patients were included if postoperative histology demonstrated RCC and if preoperative NLR was available. Patients were excluded if nephrectomy was not curative intent (i.e., cytoreductive nephrectomy), if primary tumour was graded to be T3b-4 disease, if there was presence of nodal or metastatic disease on preoperative staging, or if adequate followup notes were not available. Primary and secondary outcomes were overall survival and recurrence-free survival, respectively. RESULTS: A total of 154 patients were included in analysis of overall survival; 146 patients were included in analysis of recurrence-free survival. Patients with NLR ≤4 had a much better overall survival than patients with NLR >4 (95% vs. 78%; p=0.0219). Patients with NLR >4 also had higher rates of recurrence (p=0.0218). CONCLUSIONS: NLR may be a useful tool in identifying patients who may benefit from more frequent surveillance in the early postoperative period and may allow clinicians to offer surveillance schemes tailored to the individual patient.
INTRODUCTION: Prognosis in patients with cancer is influenced by underlying tumour biology and also the host inflammatory response to the disease. There is limited evidence to suggest that an elevated neutrophil-lymphocyte ratio (NLR) predicts a poorer prognosis in patients undergoing nephrectomy for renal cell carcinoma (RCC). The aim of this paper is to investigate if patients undergoing nephrectomy for RCC with NLR ≤4 have a better overall and recurrence-free survival than patients with NLR >4. METHODS: All patients who underwent nephrectomy at a single centre between January 1, 2011 and December 31, 2014 were identified. Patients were included if postoperative histology demonstrated RCC and if preoperative NLR was available. Patients were excluded if nephrectomy was not curative intent (i.e., cytoreductive nephrectomy), if primary tumour was graded to be T3b-4 disease, if there was presence of nodal or metastatic disease on preoperative staging, or if adequate followup notes were not available. Primary and secondary outcomes were overall survival and recurrence-free survival, respectively. RESULTS: A total of 154 patients were included in analysis of overall survival; 146 patients were included in analysis of recurrence-free survival. Patients with NLR ≤4 had a much better overall survival than patients with NLR >4 (95% vs. 78%; p=0.0219). Patients with NLR >4 also had higher rates of recurrence (p=0.0218). CONCLUSIONS: NLR may be a useful tool in identifying patients who may benefit from more frequent surveillance in the early postoperative period and may allow clinicians to offer surveillance schemes tailored to the individual patient.
Authors: Simon P Kim; Christopher J Weight; Bradley C Leibovich; R Houston Thompson; Brian A Costello; John C Cheville; Christine M Lohse; Stephen A Boorjian Journal: Urology Date: 2011-09-08 Impact factor: 2.649
Authors: S P K Jagdev; W Gregory; N S Vasudev; P Harnden; S Sim; D Thompson; J Cartledge; P J Selby; R E Banks Journal: Br J Cancer Date: 2010-11-09 Impact factor: 7.640
Authors: Boyd R Viers; Robert Houston Thompson; Stephen A Boorjian; Christine M Lohse; Bradley C Leibovich; Matthew K Tollefson Journal: Urol Oncol Date: 2014-07-10 Impact factor: 3.498
Authors: A Dirican; Y Kucukzeybek; I Somali; C Erten; L Demir; A Can; K Bahriye Payzin; I Vedat Bayoglu; M Akyol; M Koseoglu; A Alacacioglu; M Oktay Tarhan Journal: J BUON Date: 2013 Apr-Jun Impact factor: 2.533
Authors: Yoram S Baum; Dattatraya Patil; Jonathan H Huang; Stephanie Spetka; Mersiha Torlak; Peter T Nieh; Mehrdad Alemozaffar; Kenneth Ogan; Viraj A Master Journal: Asian J Urol Date: 2015-09-21
Authors: M Pichler; G C Hutterer; C Stoeckigt; T F Chromecki; T Stojakovic; S Golbeck; K Eberhard; A Gerger; S Mannweiler; K Pummer; R Zigeuner Journal: Br J Cancer Date: 2013-02-05 Impact factor: 7.640
Authors: Danielle M Bello; Katherine S Panageas; Travis Hollmann; Alexander N Shoushtari; Parisa Momtaz; Paul B Chapman; Michael A Postow; Margaret K Callahan; Jedd D Wolchok; Mary S Brady; Daniel G Coit; Charlotte E Ariyan Journal: Ann Surg Oncol Date: 2019-12-17 Impact factor: 5.344
Authors: Roy Mano; Jessica Flynn; Kyle A Blum; Andrew W Silagy; Renzo G DiNatale; Julian Marcon; Alan Wang; Alejandro Sanchez; Jonathan A Coleman; Paul Russo; Irina Ostrovnaya; A Ari Hakimi Journal: Urol Oncol Date: 2019-10-04 Impact factor: 3.498
Authors: Cathal J Hannan; Daniel Lewis; Claire O'Leary; Carmine A Donofrio; Dafydd G Evans; Emma Stapleton; Simon R Freeman; Simon K Lloyd; Scott A Rutherford; Charlotte Hammerbeck-Ward; David Brough; Stuart M Allan; David Coope; Andrew T King; Omar N Pathmanaban Journal: J Neurol Surg B Skull Base Date: 2020-09-10
Authors: Katarina Kalavska; Zuzana Sestakova; Andrea Mlcakova; Paulina Gronesova; Viera Miskovska; Katarina Rejlekova; Daniela Svetlovska; Zuzana Sycova-Mila; Jana Obertova; Patrik Palacka; Jozef Mardiak; Miroslav Chovanec; Michal Chovanec; Michal Mego Journal: Front Oncol Date: 2022-03-11 Impact factor: 6.244